Marketdash
Back to Stock Market News

Vanda Pharmaceuticals Soars on FDA Approval for First New Motion Sickness Drug in 40 Years

MarketDash Editorial Team
4 hours ago
Vanda Pharmaceuticals shares surged Wednesday after announcing FDA approval for NEREUS, the first new pharmacologic treatment for motion sickness in over four decades. The drug demonstrated significant reductions in vomiting across multiple trials.

Vanda Pharmaceuticals Inc. (VNDA) had a very good Wednesday, with shares jumping more than 27% after the company announced FDA approval for NEREUS, its novel treatment for motion sickness. If you're thinking "wait, don't we already have drugs for that?" — well, yes, but this is the first new pharmacologic option in over 40 years. That's a remarkably long gap for a condition that affects millions of people.

What Makes NEREUS Different

NEREUS (tradipitant) is an oral neurokinin-1 receptor antagonist, which is a fancy way of saying it blocks the substance P and NK-1 receptors involved in triggering nausea and vomiting. The approval came backed by solid data from three clinical studies, including two Phase 3 real-world trials with wonderful names: Motion Syros and Motion Serifos. Both studies actually took participants out on boats to induce motion sickness — because sometimes you need to test drugs in the real environment they're meant for.

The results were compelling. In the Motion Syros trial, patients taking NEREUS experienced vomiting rates between 18.3% and 19.5%, compared to 44.3% in the placebo group. Motion Serifos showed even better results, with vomiting rates ranging from 10.4% to 18.3% for NEREUS versus 37.7% for placebo. Both studies achieved statistical significance, and the drug showed a favorable safety profile consistent with acute use.

Why This Matters Beyond Seasick Tourists

Motion sickness isn't just an inconvenience for cruise passengers. Vanda pointed out that it affects a substantial portion of the population and has historically been a problem for military operational readiness — which makes sense when you're trying to run naval operations with a crew that's perpetually nauseated.

The company expects to launch NEREUS within the coming months. But here's where it gets more interesting: Vanda is also advancing tradipitant for other conditions involving nausea and vomiting, including gastroparesis and nausea induced by GLP-1 receptor agonists. That last one is particularly relevant given the explosion of GLP-1 drugs like Ozempic and Wegovy, which commonly cause nausea as a side effect.

At the time of the announcement, Vanda shares were trading 27.45% higher at $8.95, according to market data.

Back to Stock Market News

Vanda Pharmaceuticals Soars on FDA Approval for First New Motion Sickness Drug in 40 Years

MarketDash Editorial Team
4 hours ago
Vanda Pharmaceuticals shares surged Wednesday after announcing FDA approval for NEREUS, the first new pharmacologic treatment for motion sickness in over four decades. The drug demonstrated significant reductions in vomiting across multiple trials.

Vanda Pharmaceuticals Inc. (VNDA) had a very good Wednesday, with shares jumping more than 27% after the company announced FDA approval for NEREUS, its novel treatment for motion sickness. If you're thinking "wait, don't we already have drugs for that?" — well, yes, but this is the first new pharmacologic option in over 40 years. That's a remarkably long gap for a condition that affects millions of people.

What Makes NEREUS Different

NEREUS (tradipitant) is an oral neurokinin-1 receptor antagonist, which is a fancy way of saying it blocks the substance P and NK-1 receptors involved in triggering nausea and vomiting. The approval came backed by solid data from three clinical studies, including two Phase 3 real-world trials with wonderful names: Motion Syros and Motion Serifos. Both studies actually took participants out on boats to induce motion sickness — because sometimes you need to test drugs in the real environment they're meant for.

The results were compelling. In the Motion Syros trial, patients taking NEREUS experienced vomiting rates between 18.3% and 19.5%, compared to 44.3% in the placebo group. Motion Serifos showed even better results, with vomiting rates ranging from 10.4% to 18.3% for NEREUS versus 37.7% for placebo. Both studies achieved statistical significance, and the drug showed a favorable safety profile consistent with acute use.

Why This Matters Beyond Seasick Tourists

Motion sickness isn't just an inconvenience for cruise passengers. Vanda pointed out that it affects a substantial portion of the population and has historically been a problem for military operational readiness — which makes sense when you're trying to run naval operations with a crew that's perpetually nauseated.

The company expects to launch NEREUS within the coming months. But here's where it gets more interesting: Vanda is also advancing tradipitant for other conditions involving nausea and vomiting, including gastroparesis and nausea induced by GLP-1 receptor agonists. That last one is particularly relevant given the explosion of GLP-1 drugs like Ozempic and Wegovy, which commonly cause nausea as a side effect.

At the time of the announcement, Vanda shares were trading 27.45% higher at $8.95, according to market data.

    Vanda Pharmaceuticals Soars on FDA Approval for First New Motion Sickness Drug in 40 Years - MarketDash News